BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Aurobindo Pharma Ltd. reported revenue de-growth of down 3.2% YoY (down 3.2% QoQ) to Rs 58.09 billion due to 4.7% YoY (down 0.6% QoQ) decline in the U.S.' revenue (47.0% of revenue), 52.0% YoY (up 51.5% QoQ) decline in antiretroviral sales (4.1% of revenue) and a 0.8% YoY (down 9.1% QoQ) decline in Europe revenue (26.5% of revenue); partially offset by 28.0% YoY (down 1.4% QoQ) rise in growth market revenue (6.7% of revenue) and 14.9% YoY (down 9.6% QoQ) rise in active pharma ingredient revenue (15.7% of revenue).
Aurobindo Pharma's gross profit margins declined 334 bps YoY ( up 227 bps QoQ) to 56.5% in Q4 FY22 due to increased raw materials costs YoY and decline in it QoQ in Q4 FY22.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
